Vas Narasimhan, CEO of Novartis since 2017, was appointed to Anthropic's Board of Directors by the company's Long-Term Benefit Trust on April 14, 2026.
The appointment highlights AI's potential in healthcare and life sciences, with Narasimhan's experience in developing over 35 medicines praised by Anthropic's Daniela Amodei.
Anthropic recently acquired Coefficient Bio for $400 million to advance AI in drug discovery and launched Claude for Life Sciences for research tasks.
Novartis has partnered with Microsoft, Isomorphic Labs, and others to build AI capabilities.
Narasimhan emphasized responsible AI deployment in medicine, joining board members including Dario Amodei and Reed Hastings.
The Long-Term Benefit Trust ensures balance between ethics and financial success, now holding a board majority.